| A Phase I trial was carried out to assess both the safety and the immunological response of a melanoma vaccine. This vaccine incorporates the HLA-A2-restricted peptide YLEPGPVTA (gp100(280)), with the option of including a modified T-helper epitope sourced from tetanus toxoid, known as AQYIKANSKFIGITEL. AQYIKANSKFIGITEL, also referred to as TET 830 modified T-helper epitope from tetanus toxoid, serves as a universal human tetanus toxin T cell epitope. Its primary function is to induce T-cell activation, making it a valuable helper peptide in various vaccination strategies. |
